ONCAlert | Upfront Therapy for mRCC
Lung Cancer Case Studies

Case Studies: Consolidation Therapy for Locally Advanced NSCLC

Julie Brahmer, MD, reviews the case of a 59-year-old woman who presents with locally advanced non–small cell lung cancer and is treated with durvalumab after concurrent chemoradiotherapy.

Consolidation Therapy for Locally Advanced NSCLC

Case: A 59-year-old Woman With Locally Advanced NSCLC

  • A 59-year-old woman presents after referral from primary care for persistent cough and bloody sputum. She denies shortness of breath, says cough began last fall and she attributes it and the sputum to allergies.
  • History:
    • 10-year smoking history, ages 15 to 25
    • Postmenopausal, BMI = 26 kg/m2
    • Basal cell carcinoma on chest and face, had 3 lesions removed 2 years ago
  • Evaluation and follow up testing reveal stage IIIB NSCLC:
    • Radiograph shows 2 lesions in left lung (3.1 cm and 5.5 cm)
    • Fiber optic bronchoscopy identifies NSCLC
    • Endobronchial ultrasound reveals ipsilateral mediastinal lymph node involvement
    • WHO performance status 1
    • Histology: nonsquamous
    • Biomarkers
      • EGFR negative, BRAF negative, ALK/ROS1 negative
      • PD-L1 status: >25%
  • Laboratory findings:
    • WBC, renal function, hepatic function within normal ranges
  • After multidisciplinary evaluation, the patient was determined not to be a surgical candidate
  • She completed a weekly carboplatin/paclitaxel doublet therapy with concomitant radiotherapy (60 Gy)
    • Achieved partial response without progression 3 weeks later
    • Began treatment with durvalumab
Publications
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.